Advertisement

Coagulation Testing and Transfusion Medicine

  • Robert C. BlaylockEmail author
  • Christopher M. Lehman
Chapter

Abstract

Transfusion Services are presented with many challenging coagulation problems. Most cases gain attention when out of the ordinary requests for blood products are received. The Transfusion Medicine Physician is often brought into a clinical scenario that has already become an emergency and quick response is imperative [1–8]. Decisions often have to be made empirically, or with the help of a very limited coagulation test menu. This chapter will focus on maximizing information from a short coagulation test menu, reviewing the tools available to correct coagulopathies, and applying these tests to emergency situations.

Keywords

International Normalize Ratio Disseminate Intravascular Coagulation Partial Thromboplastin Time Fresh Freeze Plasma Fibrinogen Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang. 2005;89:123–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Hess JR, Zimrin AB. Massive blood transfusion for trauma. Curr Opin Hematol. 2005;12:488–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J Anaesth. 2005;95:130–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hess JR, Hiippala S. Optimizing the use of blood products in trauma care. Crit Care. 2005;9(5 Suppl):5S–10.Google Scholar
  5. 5.
    Cinà CS, Clase CM. Coagulation disorders and blood product use in patients undergoing thoracoabdominal aortic aneurysm repair. Transfus Med Rev. 2005;19:143–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev. 2003;17:223–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Hess JR, Thomas MJG. Blood use in war and disaster: lessons from the past century. Transfusion. 2003;43:1622–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma. 2003;54:454–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004;92:178–86.PubMedCrossRefGoogle Scholar
  10. 10.
    Lehman CL, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122:178–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Blaylock RC. Issues of unwashed wound drainage blood following orthopedic surgery. In: Tawes Jr RL, editor. Autotransfusion: therapeutic principles and trends. Detroit: Gregory Appleston; 1997. p. 339–43.Google Scholar
  12. 12.
    Blaylock RC, Carlson KC, Morgan JM, et al. In-vitro analysis of ‘shed blood’ from patients undergoing total knee replacement. Am J Clin Pathol. 1994;101:365–9.PubMedGoogle Scholar
  13. 13.
    McNulty SE, Sasso P, Vesci J, et al. Platelet concentrate effects on thromboelastography. J Cardiothorac Vasc Anesth. 1997;11:828–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Craft RM, Chavez JJ, Bresee SJ, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med. 2004;143:301–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Apheresis. In: Brecher ME, editor. AABB technical manual, 15th ed. Bethesda: AABB; 2005. p. 139–61.Google Scholar
  16. 16.
    Rodgers G. Acquired coagulation disorders. In: Kjeldsberg CR, editor. Practical diagnosis of hematologic disorders. 4th ed. Chicago: ASCP Press; 2006. p. 357–70.Google Scholar
  17. 17.
    Dzik W. Supplement: reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion. 2012;52 Suppl 1:45S–55.PubMedCrossRefGoogle Scholar
  18. 18.
    Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013;118:1466–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of PathologyUniversity of Utah Health Sciences CenterSalt Lake CityUSA
  2. 2.Blood BankARUP LaboratoriesSalt Lake CityUSA
  3. 3.Hospital Clinical LaboratoriesARUP LaboratoriesSalt Lake CityUSA

Personalised recommendations